medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2018, Number 5

<< Back Next >>

Rev Mex Oftalmol 2018; 92 (5)

Image markers as predictors of response in neovascular agerelated macular degeneration treated with ranibizumab

Acosta C, Sardi C, Espinosa J, Mejía ME, Sánchez JG, Arango M, Vásquez EM, Colorado M

Language: Spanish
References: 25
Page: 247-254
PDF size: 248.60 Kb.


ABSTRACT

Objective: To identify features in enhanced depth imaging spectral-domain optical coherence tomography (SD-OCT), fluorescein angiography (FA), and fundus auto fluorescence (FAF) of patients with neovascular age-related macular degenera-tion (nAMD), as image markers of poor response to intravitreal Ranibizumab therapy. Methods: Descriptive, comparative, cross sectional study. We evaluated the clinical charts of patients with nAMD on intravitreal Ranibizumab therapy. Subjects were divided into 2 groups: those with good response to Ranibizumab (G1) and those with poor response to therapy (G2). All patients underwent wide field fundus FA, wide field FAF and SD-OCT. Absolute and relative frequencies, strength of association (chi2) and prevalence ratio, with a level of significance of 95% were calculated. Results: The analysis included 30 eyes, 15 eyes in G1 and 15 eyes in G2. We found a statistically significant correlation between poor responders and the presence of external tubulations (p = 0.03). In the good responder group there was significant correlation with the presence of subretinal fluid (p = 0.04), absence of subretinal thickening (p ‹ 0.01), absence of fibrosis at the FA (p = 0.02) and presence of hyper-autofluorescent findings on the FAF (p ≤ 0.01). Conclusion: The identification of image markers prior to treatment could help predict the response to ranibizumab therapy in nAMD patients. The presence of subretinal fluid, absence of subretinal thickening, absence of fibrosis and presence of hyper-autofluorescent were associated with good responder. These markers, plus initial visual acuity can be used as a guide for categorization of patients according to response expectation, and therefore tailor the follow up scheme.


REFERENCES

  1. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004;137(3):486-95.

  2. Rein DB, Zhang P, Wirth KE, Lee PP, Hoerger TJ, McCall N, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124:1754-60.

  3. Brown DM, Kaiser PK, Michaels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-44.

  4. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239-48.

  5. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-31.

  6. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR; MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(2):246-52.

  7. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143(4):566-83.

  8. Gupta B, Adewoyin T, Patel SK, Sivaprasad S. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration. Br J Ophthalmol. 2011;95(3):386-90.

  9. Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, et al. Results of one-year’s treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol. 2009;148(3):409-13.

  10. Tsilimbaris MK, López-Gálvez MI, Gallego-Pinazo R, Margaron P, Lambrou GN. Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD. J Ophthalmol. 2016;2016:4367631.

  11. Gamulescu MA, Panagakis G, Theek C, Helbig H. Predictive Factors in OCT Analysis for Visual Outcome in Exudative AMD. J Ophthal. 2012:851684.

  12. Framme C, Wolf S, Wolf-Schnurrbusch U. Small dense particles in the retina observable by spectral-domain optical coherence tomography in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010;51(11):5965-9.

  13. Zweifel SA, Engelbert M, Laud K, Margolis R, Spaide RF, Freund KB. Outer retinal tubulation: a novel optical coherence tomography finding. Arch Ophthalmol. 2009;127(12):1596-602.

  14. Wolff B, Matet A, Vasseur V, Sahel JA, Mauget-Faÿsse M. En Face OCT Imaging for the Diagnosis of Outer Retinal Tubulations in Age-Related Macular Degeneration. J Ophthalmol. 2012;2012:542417.

  15. Mojana F, Cheng L, Bartsch DU, Silva GA, Kozak I, Nigam N, Freeman WR. The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol. 2008;146(2):218-27.

  16. Ahlers C, Golbaz I, Einwallner E, Dunavölgyi R, Malamos P, Stock G, Pruente C, Schmidt-Erfurth U. Identification of optical density ratios in subretinal fluid as a clinically relevant biomarker in exudative macular disease. Invest Ophthalmol Vis Sci. 2009;50(7):3417-24.

  17. Mathew R, Richardson M, Sivaprasad S. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab. Am J Ophthalmol. 2013;155(4):720-6.e1.

  18. Sardi Correa C, Acosta Cadavid C, Rodríguez Gómez A, Mejía Estrada M, Vásquez Trespalacios E. Grosor coroideo central en sujetos hispanos sanos medido por tomografía de coherencia óptica con imagen de profundidad mejorada. Revista Mexicana de Oftalmología. 2017; 91(1):2-8.

  19. Nakajima H, Mizota A, Tanaka M. Technical note: method for estimating volume of subretinal fluid in cases of localized retinal detachment by OCT ophthalmoscopy. Ophthalmic Physiol Opt. 2007;27(5):512-7.

  20. Brown DM, Tuomi L, Shapiro H. Pier Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration. Retina. 2013;33(1):23-34.

  21. Singh RP, Fu EX, Smith SD, Williams DR, Kaiser PK. Predictive factors of visual and anatomical outcome after intravitreal bevacizumab treatment of neovascular age- related macular degeneration: an optical coherence tomography study. Br J Ophthalmol. 2009;1353-8.

  22. Roberts P, Mittermueller TJ, Montuoro A, Sulzbacher F, Munk M, Sacu S, Schmidt-Erfurth U. A quantitative approach to identify morphological features relevant for visual function in ranibizumab therapy of neovascular AMD. Invest Ophthalmol Vis Sci. 2014;55(10):6623-30.

  23. Young M, Forooghian F. Serous Index of Pigment Epithelial Detachments in Neovascular Age-Related Macular Degeneration Predicts Response to Anti-Vascular Endothelial Growth Factor Treatment. Ophthalmic Surg Lasers Imaging Retina. 2015;46(7):724-7.

  24. Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Design, Development and Therapy. 2016;10:1857-67.

  25. Otsuji T, Nagai Y, Sho K, Tsumura A, Koike N, Tsuda M, Nishimura T, Takahashi K. Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD). Clin Ophthalmol. 2013; 7:1487-90.




2020     |     www.medigraphic.com